FPCG
ALZN icon

Forum Private Client Group’s Alzamend Neuro ALZN Stock Holding History

Forum Private Client Group’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12
Closed -$20K – 68
2022
Q1 		$20K Buy
+12
New +$22.5K 0.02% 64

Other funds holding ALZN

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $65.6M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Forum Private Client Group's ALZN Position: Q2 2022 in Review

Forum Private Client Group sold out of Alzamend Neuro (ALZN) in Q2 2022, closing a stake of 12 shares — an estimated $20K sold.

Forum Private Client Group first reported a position in ALZN in Q1 2022 and held it in 1 quarter. The position peaked at $20K in Q1 2022. 20 funds tracked by Wall St. Rank hold ALZN as of Q2 2022.

  • Forum Private Client Group reported no remaining Alzamend Neuro position as of Q2 2022 after selling out during the quarter.
  • Forum Private Client Group sold 12 Alzamend Neuro shares in Q2 2022, an estimated $20K.
  • Forum Private Client Group first reported a position in Alzamend Neuro in Q1 2022 and held it in 1 quarter.
  • Forum Private Client Group's Alzamend Neuro position peaked at $20K in Q1 2022.
  • 20 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2022.

Based on Forum Private Client Group's 13F filing for Q2 2022, filed 5 Aug 2022.